Jamie L Todd,^1,2 Megan L Neely,^1,2 Robert Overton,¹ Hillary Mulder,¹ Jesse Roman,³ Joseph A Lasky,⁴ Joao de Andrade,⁵ Mridu Gulati,⁶ Howard Huang,⁷ Thomas B Leonard,⁸ Christian Hesslinger,⁹ Imre Noth,¹⁰ John A Belperio,¹¹ Kevin R Flaherty,¹² Scott M Palmer^1,2 on behalf of the IPF-PRO Registry investigators

¹Duke Clinical Research Institute, Durham, North Carolina, USA; ²Duke University Medical Center, Durham, North Carolina, USA; ³Jane and Leonard Korman Respiratory Institute, Philadelphia, Pennsylvania, USA; ⁴School of Medicine, Tulane University, New Orleans, Louisiana, USA; ⁵Vanderbilt University School of Medicine, Nashville, Tennessee, USA; ⁶Yale School of Medicine, New Haven, Connecticut, USA; ⁷Houston Methodist Hospital, Houston, Texas, USA; ⁸Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, Connecticut, USA; ⁹Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; ¹⁰Division of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia, USA; ¹¹David Geffen School of Medicine at UCLA, Los Angeles, California, USA; ¹²Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA.